Abstract
Background: Certain antidepressants act as photosensitizers and may affect skin cancer risk; however, no evidence synthesis has been conducted. With the rising global incidence of skin cancer and widespread antidepressant use, clarifying any potential association is essential for public health.
Objectives: To assess the association between prescribed antidepressants and skin cancer (basal cell carcinoma, cutaneous squamous cell carcinoma and melanoma) risk.
Methods: The protocol was registered on PROSPERO. MEDLINE and Embase were searched on 5 October 2025. Titles, abstracts and full texts were screened, and the methodologies appraised by two independent reviewers. The Mantel–Haenszel method (random-effects model) was applied to pool odds ratios (ORs), and the inverse variance method was used for rate ratios (RRs); heterogeneity was assessed using I2. The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) framework assessed the certainty of evidence. Subgroup analyses included a comparison of skin cancer risk between selective serotonin reuptake inhibitors (SSRIs) and non-SSRIs.
Results: Ten studies were included, five of which contributed to the meta-analysis. The association between antidepressant use and skin cancer risk was not statistically significant [RR 0.83, 95% confidence interval (CI) 0.60–1.16 (P = 0.28, I2 = 87%); OR 0.93, 95% CI 0.85–1.02 (P = 0.12, I2 = 69%)]. The subgroup analysis results for those who did and did not use SSRIs were similar and showed no statistically significant associations with skin cancer risk. The certainty of evidence was very low.
Conclusions: No statistically significant association was found between antidepressant use and skin cancer risk. Further high-quality research considering important confounders such as skin type, skin cancer type, sun exposure-related behaviour and sufficient follow-up is needed to confirm these findings.
Objectives: To assess the association between prescribed antidepressants and skin cancer (basal cell carcinoma, cutaneous squamous cell carcinoma and melanoma) risk.
Methods: The protocol was registered on PROSPERO. MEDLINE and Embase were searched on 5 October 2025. Titles, abstracts and full texts were screened, and the methodologies appraised by two independent reviewers. The Mantel–Haenszel method (random-effects model) was applied to pool odds ratios (ORs), and the inverse variance method was used for rate ratios (RRs); heterogeneity was assessed using I2. The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) framework assessed the certainty of evidence. Subgroup analyses included a comparison of skin cancer risk between selective serotonin reuptake inhibitors (SSRIs) and non-SSRIs.
Results: Ten studies were included, five of which contributed to the meta-analysis. The association between antidepressant use and skin cancer risk was not statistically significant [RR 0.83, 95% confidence interval (CI) 0.60–1.16 (P = 0.28, I2 = 87%); OR 0.93, 95% CI 0.85–1.02 (P = 0.12, I2 = 69%)]. The subgroup analysis results for those who did and did not use SSRIs were similar and showed no statistically significant associations with skin cancer risk. The certainty of evidence was very low.
Conclusions: No statistically significant association was found between antidepressant use and skin cancer risk. Further high-quality research considering important confounders such as skin type, skin cancer type, sun exposure-related behaviour and sufficient follow-up is needed to confirm these findings.
| Original language | English |
|---|---|
| Journal | Skin Health and Disease |
| DOIs | |
| Publication status | Published - 17 Apr 2026 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver